New research indicates that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight much more quickly than those who end traditional lifestyle regimens.
Research printed in a prominent health publication demonstrates that while obese people can lose about a fifth of their body weight while on the medication, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Individuals buying these drugs should be aware of the potential of quick weight regain when the medication is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery implies a return to starting weight in about a year and a half.
Comparing Treatments
The study, which looked at dozens of studies involving thousands of participants, compared the results of GLP-1 agonists with other pills.
The team note that individuals who shed pounds through diet and exercise generally have a more gradual creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Quick Regain
Doctors believe the mechanism of the injections accounts for the accelerated regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal may cause the body to produce less of its own natural hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication leads to appetite is unsuppressed, making excessive eating a significant risk."
A Lifelong Condition?
Health authorities suggest the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals contend that, given the high risk of relapse, the treatment should be considered ongoing.
This perspective is reinforced by pharmaceutical companies, who state that the findings "underscore the persistent character of obesity," comparing it to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the jabs report a sudden resurgence of hunger.
"It was like something flipping and I was suddenly starving," recalled one woman.
This challenge is exacerbated if patients have not established lasting lifestyle or habit changes during treatment.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Use is higher among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, researchers caution that while these medications are potent tools for shedding pounds, they are not a standalone cure and long-term success hinges on ongoing lifestyle support.